↓ Skip to main content

Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries

Overview of attention for article published in International Journal of Cancer, May 2003
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

patent
1 patent
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
29 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries
Published in
International Journal of Cancer, May 2003
DOI 10.1002/ijc.11208
Pubmed ID
Authors

Uta Behrends, Inken Schneider, Sabine Rössler, Heinrich Frauenknecht, Anja Golbeck, Brigitte Lechner, Gerhard Eigenstetter, Colette Zobywalski, Stephan Müller-Weihrich, Ulrike Graubner, Irene Schmid, Dieter Sackerer, Manfred Späth, Claudia Goetz, Franz Prantl, Hans-Peter Asmuss, Karl Bise, Josef Mautner

Abstract

Medulloblastoma is an embryonal childhood malignancy with poor prognosis. By screening 4 medulloblastoma cDNA expression libraries (SEREX) with autologous sera, 15 different antigens were identified. These antigens were encoded by 3 novel genes, genes of unknown function (KIAA0445, KIAA1853, KIAA0665, FLJ13942, HSPC213), a proto-oncogene (rab18), candidate tumor suppressor genes (BAP1, PRDM13) and genes encoding a motor protein (kinesin-2), a histone (H2A1.2), the ankyrin residue-rich nasopharyngeal cancer susceptibility protein (NZ16) and the transcription factor TZP, which is homologous to the tumor-associated antigens HCA58 and GLEA2. In a consecutive analysis of serum antibody titers and tumor load, a more than 10-fold increase in serum antibodies against PRDM13 preceded the clinical diagnosis of recurrent tumor growth in a patient with aggressive large cell medulloblastoma. When sera of pediatric patients with cancer (n = 40) and healthy controls (n = 40) were tested for humoral responses against the SEREX-defined antigens, 5 antigens were exclusively recognized by sera from cancer patients. These antigens included a novel rab18 gene product translated from mRNA sequences formerly described as 3' untranslated region. Humoral responses against 2 of the remaining 10 antigens were found preferentially in cancer patients. Antibodies against these antigens were detected in 8/40 and 12/40 cancer patients, respectively, but in only 1 healthy control. The 2 antigens were characterized by a tumor-specific deletion and a tumor-specific mutation, respectively. These findings indicate that the humoral immune response against medulloblastoma is directed against diverse antigens that may be useful as diagnostic markers or targets for immunotherapy.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Unknown 28 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 34%
Student > Bachelor 5 17%
Student > Ph. D. Student 5 17%
Student > Postgraduate 2 7%
Student > Doctoral Student 1 3%
Other 3 10%
Unknown 3 10%
Readers by discipline Count As %
Agricultural and Biological Sciences 16 55%
Biochemistry, Genetics and Molecular Biology 6 21%
Immunology and Microbiology 1 3%
Neuroscience 1 3%
Unknown 5 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2017.
All research outputs
#2,075,444
of 12,145,106 outputs
Outputs from International Journal of Cancer
#1,291
of 8,773 outputs
Outputs of similar age
#55,384
of 276,904 outputs
Outputs of similar age from International Journal of Cancer
#23
of 97 outputs
Altmetric has tracked 12,145,106 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,773 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,904 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.